- Helix, CDC Expand Partnership to Advance Viral Surveillance Program
- Hartford Healthcare Partnership Focuses on Digital Health Innovation
“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology, and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” Teiichi Goto, president, CEO, and representative director of Fujifilm Corporation, said in a press release.
“We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”
Inspirata's Dynamyx is an end-to-end digital pathology solution using whole-slide images to digitize patient results. The software capabilities are typically implemented within more extensive medical facilities handling large volumes of pathological images across several lab locations.
“A $320 million global industry in 2021 projected to reach $640 million by 2025, the rising number of cancer cases and the demonstrated benefits of digital pathology are fueling significant demand and market growth in the hospital and pharmaceutical industries,” Henry Izawa, president and CEO of Fujifilm Healthcare Americas Corporation, said. “These evolving clinical needs fuel Fujifilm’s investment and innovation in the digital revolution, and we look forward to introducing Dynamyx and its host of unique features and benefits to our Synapse customers and prospects as we strive to enable more efficient medical diagnosis and high-quality care.”
This is just one organization leveraging digital pathology technology to advance patient care.
PreciseDx, a Mount Sinai Health System spin-off, developed an artificial intelligence-enabled digital pathology technology to detect early-onset Parkinson’s disease (PD).
According to an April study, the technology detected Parkinson's pathology in image patches from biopsy samples with 99 percent sensitivity and 99 percent specificity.
"These findings show the potential for technology to aid in the diagnosis of Parkinson's disease," Jamie Eberling, PhD, senior vice president of research resources at MJFF, said in the press release. "Objective diagnostic tools, especially early in the disease, are critical to drive care decisions and to design trials toward better treatments and cures."
By 